Rituximab done: what's next in rheumatoid arthritis? A European observational longitudinal study assessing the effectiveness of biologics after rituximab treatment in rheumatoid arthritis

Rheumatology
Ulrich A WalkerCem Gabay

Abstract

To compare the effectiveness of biologics after rituximab (RTX) treatment in RA. The effectiveness of TNF-α inhibitors (TNFi), abatacept (ABA) or tocilizumab (TCZ) was examined in patients previously treated with RTX using clinical data collected in the Collaborative Registries for the Evaluation of Rituximab in RA Collaborative registry. Patients had stopped RTX 6 months or less prior to the new biologic and had a baseline visit within 21 days of starting the new biologic. Two hundred and sixty-five patients were analysed after 6 months of treatment. Patients on TCZ (n = 86) had a greater decline of DAS28-ESR and clinical disease activity index than patients on TNFi (n = 89) or ABA (n = 90). This effect was also seen after adjusting for baseline prednisone use and the number of previous biologics. The mean DAS28-ESR scores in patients on TCZ were 1.0 (95% CI: 0.2, 1.7) and 1.8 (95% CI: 1.0, 2.5) points lower than in patients on TNFi or ABA, respectively. In patients on TCZ, the clinical disease activity index was 9.4 (95% CI: 1.7, 16.1) and 8.1 (95% CI: 0.9, 15.3) points lower than on TNFi and ABA, respectively. Patients on TCZ more frequently had good EULAR responses than patients on TNFi or ABA (66 vs 31 vs 14%, P < 0.001). ...Continue Reading

References

Oct 20, 1998·Arthritis and Rheumatism·A M van GestelP L van Riel
Sep 16, 2005·The New England Journal of Medicine·Mark C GenoveseMaxime Dougados
May 1, 2007·Arthritis and Rheumatism·Axel FinckhUNKNOWN Physicians of the Swiss Clinical Quality Management Program for Rheumatoid Arthritis
Jan 22, 2009·Annals of the Rheumatic Diseases·M C GenoveseT M Shaw
Dec 8, 2009·Rheumatic Diseases Clinics of North America·Jaap Fransen, Piet L C M van Riel
Dec 8, 2009·Rheumatic Diseases Clinics of North America·Daniel Aletaha, Josef S Smolen
Jan 22, 2010·Rheumatology International·Richa MishraCharles H Pritchard
Aug 19, 2010·Rheumatology·Ulrich A WalkerUNKNOWN Swiss Clinical Quality Management Programme in Rheumatic Diseases

❮ Previous
Next ❯

Citations

Apr 14, 2016·Ocular Immunology and Inflammation·Denis WakefieldStephan Thurau
Jun 25, 2016·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Mar Maldonado-MontoroMiguel Ÿngel Calleja-Hernández
Dec 14, 2016·The Pharmacogenomics Journal·M Maldonado-MontoroM Ángel Calleja-Hernández
Jan 27, 2019·BMJ : British Medical Journal·Jacques-Eric GottenbergUNKNOWN French Society of Rheumatology and the investigators participating in AIR, ORA, and REGATE registries
Oct 13, 2017·American Journal of Therapeutics·Tristan PascartRené-Marc Flipo
Aug 20, 2021·Annals of the Rheumatic Diseases·György NagyJacob M van Laar

❮ Previous
Next ❯

Related Concepts

Related Feeds

Autoimmune Disease Therapy

In autoimmune diseases, the immune system responds and attacks self-antigens and damages or impairs the function of the tissues. The treatment for autoimmune diseases often involves immunosuppressive agents, but newer treatments are being investigated. Discover the latest research on autoimmune disease therapy here.